Kiniksa Pharmaceuticals International (KNSA) Net Cash Flow (2017 - 2026)
Kiniksa Pharmaceuticals International's (KNSA) quarterly Net Cash Flow came in at -$14.3 million in Q2 2026, down 140.9% YoY from $34.9 million in Q2 2025, and down 158.61% on a QoQ basis from $24.4 million in Q1 2026.
Kiniksa Pharmaceuticals International (KNSA) Net Cash Flow (2017 - 2026) Analysis & Trends
Kiniksa Pharmaceuticals International (KNSA) has 10 years of Net Cash Flow data on file, last reported at -$14.3 million in Q2 2026.
- Quarterly Net Cash Flow fell 140.9% year-over-year to -$14.3 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$16.4 million (down 117.64% YoY) and the FY2025 annual result came in at -$18.0 million, down 123.78% from the prior year.
- Net Cash Flow eased to -$14.3 million in Q2 2026, from $24.4 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $86.2 million in Q4 2024 to a low of -$59.1 million in Q1 2022.
- A 5-year average of $3.0 million and a median of -$5.6 million in 2024 frame the typical range for Net Cash Flow.
- Annual changes were most pronounced in 2022 — Net Cash Flow plunged 1116.6% — and 2024, when it jumped 973.05%.
- Tracing KNSA's Net Cash Flow over 5 years: stood at -$53.0 million in 2022, then soared by 81.39% to -$9.9 million in 2023, then jumped by 973.05% to $86.2 million in 2024, then slumped by 110.74% to -$9.3 million in 2025, then plunged by 54.12% to -$14.3 million in 2026.
- The last three Net Cash Flow figures came in at -$14.3 million (Q2 2026), $24.4 million (Q1 2026), and -$9.3 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | -81.00 Mn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | -458.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | -881.03 Mn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 523.50 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | -912.40 Mn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 64.40 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 93.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Kiniksa Pharmaceuticals International | 6.14 Bn | 5.61 Bn | 220.03 Mn | -14.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -14.28 Mn |
| Jun 30, 2026 | -14.28 Mn |
| Mar 31, 2026 | 24.36 Mn |
| Mar 31, 2026 | 24.36 Mn |
| Dec 31, 2025 | -9.26 Mn |
| Dec 31, 2025 | -9.26 Mn |
| Sep 30, 2025 | -17.18 Mn |
| Sep 30, 2025 | -17.18 Mn |
| Jun 30, 2025 | 34.91 Mn |
| Jun 30, 2025 | 34.91 Mn |
| Mar 31, 2025 | -26.45 Mn |
| Mar 31, 2025 | -26.45 Mn |
| Dec 31, 2024 | 86.21 Mn |
| Dec 31, 2024 | 86.21 Mn |
| Sep 30, 2024 | -1.90 Mn |
| Sep 30, 2024 | -1.90 Mn |
| Jun 30, 2024 | -41.81 Mn |
| Jun 30, 2024 | -41.81 Mn |
| Mar 31, 2024 | 33.12 Mn |
| Mar 31, 2024 | 33.12 Mn |